Anixa Biosciences, Inc.
ANIX
$3.09
-$0.17-5.22%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.96% | 10.08% | -4.65% | -16.19% | -27.96% |
| Total Depreciation and Amortization | -2.70% | -10.00% | -37.50% | -31.25% | -19.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.41% | -24.04% | -14.46% | -12.58% | 0.87% |
| Change in Net Operating Assets | -71.10% | 156.47% | 100.66% | 148.91% | 149.62% |
| Cash from Operations | 2.21% | 18.29% | -11.12% | -21.44% | -18.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.80% | 80.36% | 1,072.52% | 240.14% | 176.33% |
| Cash from Investing | 13.80% | 80.36% | 1,072.52% | 240.14% | 176.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -30.74% | -44.83% | -91.52% | 686.28% | 842.08% |
| Repurchase of Common Stock | 90.91% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 111.51% | -- | -200.77% | -- |
| Cash from Financing | -33.24% | -43.26% | -92.56% | -56.78% | 833.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.58% | 113.68% | 119.78% | 100.63% | 103.11% |